-
Posted by
Two Blokes 7 hours ago -
Filed in
Stock
-
2 views
Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the stock's recent gains stem from a low base, and it still trades well below its 2021 highs. Earnings growth is steady but uninspiring, with margin pressure and tariff risks highlighting operational challenges versus higher-quality competitors.
